Clinical approach to pancreatic cystic lesions
Moderator
Dr. Nikhil Agrawal
GI-HPB Surgeon & Oncologist
Max Superspeciality Hospital, Saket
Panelists
Dr. Vikas Singla
Gastroenterologist
Max Superspeciality Hospital, Saket
Dr. Asit Arora
GI-HPB Onco Surgeon
Max Superspeciality Hospital, Saket
Dr. Balkishan Gupta
Minimally invasive Surgeon
QRG Health City, Faridabad
Dr. Manu Shankar
General and Bariatric Surgeon
Fortis Escorts Hospital, Faridabad
Introduction
- Increasingly diagnosed incidentally
- Sequalae of pancreatitis
- Approximately 1-3.5% malignant
- Treatment options range from observation to radical surgery
- Depends on malignant potential
- Highest malignant risk in mucinous cysts
- Pseudocyst is treated if symptomatic or complicated
Types
Benign/Inflammatory Lesions
- Pseudocysts/ WOPN
- Infectious cyst
- Retention cyst
- Lymphoepithelial cyst
- Congenital cyst
- Serous cystadenoma
Cystic Lesions with Malignant Potential
- Intraductal papillary mucinous neoplasm (IPMN)
- Mucinous cystadenoma
- Cystic pancreatic neuroendocrine neoplasms
- Solid pseudopapillary neoplasms
- Cystic malignant tumours (cystic degeneration)
- Cystic ductal adenocarcinoma
- Acinar cancers
History and Presentation
- H/o severe pain abdomen
- H/o Pancreatitis
- Chronic pancreatitis
- Pain abdomen
- Jaundice (yellowing of eyes, skin and urine)
- Feeling of fullness after food or bloating
- Lump in the abdomen
- Incidental
Distinguishing Between Lesions
- History and clinical
- Radiological/ EUS
- Fluid analysis
Work-up
- Ultrasound
- CECT abdomen
- CEMRI
- Endoscopic ultrasound
Radiological Features
- Location
- Ductal relation
- Internal content
- External contour/Wall
- Septal enhancement
High Malignancy Risk Features
- Mural nodules
- Nearby mass
- Thick septa
- Dilated PD
Pathological Features - Cyst Fluid Analysis
- CEA, CA-125, mucin content, cytology, DNA content, detection of genetic mutations
- Cyst fluid glucose
- CEA most reliable - Sensitivity and specificity 73% and 84%
- Cyst fluid mucin content analysis
- MUC1 - pancreatic adenocarcinoma
- MUC 6 - serous cysts
- Cysts with MUC 5A, MUC2 and MUC 1 have the highest risk of being malignant
- Molecular analysis - K-ras mutation and >2 loss of heterozygosity was 96.2% specific for malignancy
Pseudocyst / WOPN
Collection of inflammatory debris lined by a false wall of granulation tissue. May be asymptomatic, symptomatic, infected or complicated (bleed, obstruction [gastric, biliary], rupture).
- Cyst fluid high amylase and lipase
- CT — unilocular hypodense cystic lesions surrounded by smooth dense wall having contrast enhancement
- Radiological evidence of pancreatitis
Management
Observation
- Simple cyst
- Lymphoepithelial cysts
- Small serous cystic neoplasm
- Small branch duct IPMN
- Intraparenchymal spleen
Surgery
Those deemed malignant and at risk of malignancy. Depending on the location and size:
- Whipple
- Distal pancreatectomy
- Spleen preserving
- Central pancreatectomy
- Enucleation
Approach
- Open
- Laparoscopic
About Author
Dr. Nikhil Agrawal
MS, MCh
Dr. Nikhil Agrawal is a leading GI-HPB Surgical Oncologist with 20+ years of experience in complex cancers of the esophagus, stomach, colon, rectum, liver, pancreas, gallbladder, and bile ducts. He leads the GI-HPB Oncology Program at Apollo Hospitals, Delhi and Gurugram, with expertise in advanced robotic and laparoscopic cancer surgery.
His practice focuses on evidence-based, multidisciplinary care with an emphasis on individualized treatment and long-term outcomes.
He trained at BHU, SGPGI Lucknow, AIIMS New Delhi, and SNUBH, South Korea, and is a robotic surgery proctor who trains surgeons in advanced GI-HPB cancer surgery. He is also regularly invited as faculty at national and international scientific meetings.
This website helps patients and families understand GI and HPB diseases and cancers, treatment options, and what to expect during recovery and long-term care.